The civic record
Read. Follow. Verify.Proposed Faster Approval Process for Over-the-Counter Drugs
Last action · July 20, 2026: Referred to the House Committee on Energy and Commerce.Sponsors: Robert Latta and 1 other
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
This bill proposes a new, faster FDA review process for certain to reach store shelves more quickly. It aims to create an expedited pathway for medications that meet specific priority criteria.
If passed, this could reduce the time it takes for new over-the-counter medications to become available to consumers, potentially increasing the variety of self-care options in pharmacies.
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Consumers
Consumers may gain access to new over-the-counter medications more quickly if the expedited approval process is implemented.
Pharmaceutical companies
Companies developing nonprescription drugs may experience shorter wait times for product approval.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
What does 'expedited approval' mean for consumers?
Does this bill change safety standards?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
2 actions- Jul 20, 2026HouseCommitteeReferred to the House Committee on Energy and Commerce.
- Jul 20, 2026HouseIntroducedIntroduced in House
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Regulatory Acceleration
The bill signals a legislative intent to prioritize speed in the nonprescription drug market, potentially shifting FDA resource allocation.
Connected Entities
Sources
www.congress.gov
Analysis Score
0–100- Significance60How much this matters to a regular citizen
- Controversy20Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz15Current news / social attention level
Publisher tools